Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Phase 1

Recruiting

Conditions: Colorectal Adenocarcinoma
Ewing Sarcoma

Interventions: Drug: INBRX-109
Drug: 5-fluorouracil
Drug: Carboplatin
Drug: Irinotecan
Drug: Temozolomide
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2018-10-23

Last Posted Date: 2024-12-12

Lead Sponsor: Inhibrx Biosciences, Inc

Target Recruit Count: 321

Registration Number: NCT03715933

Locations: 🇺🇸
Precision NextGen Oncology and Research, Beverly Hills, California, United States
🇺🇸
University of California, San Francisco (UCSF), San Francisco, California, United States
🇺🇸
Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia, Pennsylvania, United States

and more 31 locations

Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma

Phase 2

Conditions: Advanced LKB1-inactive Lung Adenocarcinoma

Interventions: Drug: Metformin Hydrochloride
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed
Dietary Supplement: Fasting-mimicking diet
Drug: Pembrolizumab

First Posted Date: 2018-10-17

Last Posted Date: 2020-11-16

Lead Sponsor: Marina Garassino

Target Recruit Count: 64

Registration Number: NCT03709147

Locations: 🇮🇹
Marina Chiara Garassino, Milan, Italy

Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 3

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Camrelizumab
Drug: Placebos
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2018-10-16

Last Posted Date: 2022-07-01

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 263

Registration Number: NCT03707509

Locations: 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China

Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Phase 3

Active, not recruiting

Conditions: Nasopharyngeal Neoplasms

Interventions: Drug: Sintilimab
Drug: Gemcitabine
Drug: Cisplatin
Radiation: intensity-modulated radiotherapy

First Posted Date: 2018-10-09

Last Posted Date: 2023-03-28

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 425

Registration Number: NCT03700476

Locations: 🇨🇳
Panyu central hospital, Guangzhou, Guangdong, China
🇨🇳
Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

and more 6 locations

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Phase 1

Withdrawn

Conditions: Metastatic Pancreatic Cancer
Pancreatic Cancer
Pancreas Cancer
Pancreatic Adenocarcinoma Resectable
Pancreatic Ductal Adenocarcinoma
Pancreatic Metastasis

Interventions: Drug: Ascorbic Acid
Drug: Paclitaxel protein-bound
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2018-10-05

Last Posted Date: 2019-06-11

Lead Sponsor: Hitendra Patel

Registration Number: NCT03697239

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial

Phase 2

Completed

Conditions: Anal Canal Squamous Cell Carcinoma
Stage I Anal Cancer AJCC v8
Stage II Anal Cancer AJCC v8
Stage IIA Anal Cancer AJCC v8
Stage IIB Anal Cancer AJCC v8
Stage III Anal Cancer AJCC v8
Stage IIIA Anal Cancer AJCC v8
Stage IIIC Anal Cancer AJCC v8
Stage IIIB Anal Cancer AJCC v8

Interventions: Drug: Cisplatin
Drug: Fluorouracil
Radiation: Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
Procedure: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2018-10-01

Last Posted Date: 2023-06-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT03690921

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

Phase 3

Completed

Conditions: Advanced Esophageal Cancer

Interventions: Drug: Placebo
Drug: SHR-1210
Drug: paclitaxel
Drug: cisplatin

First Posted Date: 2018-10-01

Last Posted Date: 2022-12-07

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 596

Registration Number: NCT03691090

Locations: 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

Phase 3

Terminated

Conditions: Recurrent Ovarian Carcinoma

Interventions: Drug: Carboplatin
Drug: Gemcitabine
Drug: Trabectedin
Drug: Bevacizumab
Drug: PLD
Drug: Paclitaxel
Drug: Cisplatin

First Posted Date: 2018-10-01

Last Posted Date: 2022-02-24

Lead Sponsor: AGO Research GmbH

Target Recruit Count: 9

Registration Number: NCT03690739

Locations: 🇩🇪
Sozialstiftung Bamberg, Bamberg, Germany
🇩🇪
Kreiskrankenhaus "Johann Kentmann", Torgau, Germany
🇩🇪
Hochtaunus-Kliniken, Bad Homburg, Germany

and more 26 locations

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

Phase 3

Active, not recruiting

Conditions: Stomach Neoplasms

Interventions: Biological: Pembrolizumab
Drug: Cisplatin
Drug: 5-fluorouracil
Drug: oxaliplatin
Drug: Placebo for Pembrolizumab
Drug: capecitabine

First Posted Date: 2018-09-18

Last Posted Date: 2024-12-02

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1579

Registration Number: NCT03675737

Locations: 🇨🇷
CIMCA Centro de Investigacion y Manejo del Cancer ( Site 3001), San Jose, Costa Rica
🇨🇷
Policlinico San Bosco ( Site 3002), San Jose, Costa Rica
🇨🇷
ICIMED - Instituto de Investigacion en Ciencias Medicas ( Site 3000), San Jose, Costa Rica

and more 212 locations

Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC

Phase 3

Completed

Conditions: Incidental Gallbladder Carcinoma
Biliary Tract Cancer

Interventions: Drug: Gemcitabine
Drug: Cisplatin
Drug: Adjuvant chemotherapy
Procedure: Oncologically radical margin-free (R0) resection

First Posted Date: 2018-09-17

Last Posted Date: 2024-11-12

Lead Sponsor: Krankenhaus Nordwest

Target Recruit Count: 68

Registration Number: NCT03673072

Locations: 🇩🇪
Krankenhaus Nordwest gGmbH, Frankfurt, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy